# US 2020/0392126 A1 · Isoxazolyl compounds as receptor modulating compounds and methods and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392126 A1
- Document ID: US20200392126A1
- Status: Published application
- Kind: A1
- Application number: 16/769,757
- Filed: 2018-11-26
- Published: 2020-12-17
- Earliest claimed: 2017-12-05
- Assignees: Bionomics Limited
- Applicants: Bionomics Limited
- Inventors: Justin Anthony RIPPER; Patrick BAZZINI; Jean-Marie CONTRERAS; Nicolas FEICHTER; Christophe MORICE; Laurent SCHAEFFER; Cindy STAHL
- Web page: https://patentgrep.com/patent/US20200392126A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 261/10: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which are useful in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention also relates to the use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.

## Claims

### Claim 1

A compound of formula (I) or pharmaceutically acceptable salts thereof:
wherein R1 is selected from optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted 6-membered heteroaryl; and
R2 is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted acyl, or optionally substituted oxyacyl; and
R3 and R4 are independently selected from H, hydroxyl, optionally substituted alkyl, optionally substituted alkoxyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted cycloalkenyl; or
R3 and R4 can be linked to form optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted cycloalkenyl; and
L is a single bond, N, CH, or a divalent linker selected from CH2, optionally substituted C3-C6 cycloalkylene and optionally substituted C3-C6 cycloalkenylene; or
R2 and L can be linked to form optionally substituted N-containing heterocyclyl where L is N or CH; or
R2 and R1 can be linked to form optionally substituted N-containing heterocyclyl where L is CH2; and
m is an integer selected from 1 to 5,
excluding the following two compounds:

### Claim 2 (depends on 1)

A compound of claim 1 or pharmaceutically acceptable salt, solvate, prodrug, stereoisomer or tautomer thereof selected from the sub-formulae:
wherein R1, R2, R3, R4, L and m are as defined above in claim 1;
wherein Y is where one R3 and R4 is linked together to form optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted cycloalkenyl;
wherein Z is where R2 and L is linked together to form optionally substituted N-containing heterocyclyl where L is N or CH;
wherein T is where R2 and R1 is linked together to form optionally substituted N-containing heterocyclyl where L is CH2; and
m′ is 0 or 1.

### Claim 3 (depends on 2)

A compound of claim 2, wherein the sub-formulae is selected from (Ia) or (Ib).

### Claim 4 (depends on 1, 2, 3)

A compound of any one of claims 1 to 3, wherein R1 is selected from phenyl, oxazolyl, pyrrolyl, imidazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolizinyl, isoquinolinyl, quinolinyl, phthalazinyl, naphthylpyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, isothiazolyl, phenazinyl, isoxazolyl, isothiazolyl, phenoxazinyl, phenothiazinyl, imidazolidinyl, imidazolinyl, piperidinyl, piperazinyl, indolinyl, phthalimidyl, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7 -tetrahydrobenzo[b] thiophenyl, thiazolyl, thiadiazolyl, oxadiazolyl, oxatriazolyl, tetrazolyl, thiazolidinyl, thiophenyl, benzo[b]thiophenyl, morpholinyl, piperidinyl, pyrrolidinyl, tetrahydrofuranyl, or triazolyl,
wherein any one of these groups may be optionally substituted with one to three substituents independently selected from hydroxy, halogen (in particular Cl, Br, F), C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl (such as —CFA C1-6 haloalkoxy (such as —OCF3), C2-6 alkenyloxy, C2-6 alkynyloxy, arylalkyl (wherein alkyl is C1-6), arylalkoxy (wherein alkyl is C1-6), aryl, cyano, nitro, heteroaryl, C1-6 heteroarylalkyl (wherein alkyl is C1-6), heteroaryloxy, heterocyclyl, heterocyclylalkyl (wherein alkyl is C1-6), heterocyclyloxy, acyl, oxyacyl, trialkylsilyl, trifluoromethanethio, amino, mono- and di(C1-C6)-alkylamino, mono-and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroarylamino, mono- and di-heterocyclyl amino (including unsymmetric di-substituted amines having different substituents selected from alkyl, aryl, heteroaryl and heterocyclyl).

### Claim 5 (depends on 4)

A compound of claim 4, wherein R1 is phenyl optionally substituted with one to three substituents independently selected from hydroxy, halogen (in particular Cl, Br, F), C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl (such as —CF3), C1-6 haloalkoxy (such as —OCF3), C2-6 alkenyloxy, C2-6 alkynyloxy, arylalkyl (wherein alkyl is C1-6), arylalkoxy (wherein alkyl is C1-6), aryl, cyano, nitro, heteroaryl, C1-6 heteroarylalkyl (wherein alkyl is C1-6), heteroaryloxy, heterocyclyl, heterocyclylalkyl (wherein alkyl is C1-6), heterocyclyloxy, acyl, oxyacyl, trialkylsilyl, trifluoromethanethio, amino, mono- and di(C1-C6)-alkylamino, mono-and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroarylamino, mono- and di-heterocyclyl amino (including unsymmetric di-substituted amines having different substituents selected from alkyl, aryl, heteroaryl and heterocyclyl).

### Claim 6 (depends on 3)

A compound of claim 3, wherein R2 is selected from H, optionally substituted C1-C3 alkyl, or optionally substituted C3-C6 heterocyclyl.

### Claim 7 (depends on 6)

A compound of claim 6, wherein the sub-formulae is (Ia) and m is 1 to 3 and R3 and R4 is independently selected from H, hydroxyl, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl.

### Claim 8 (depends on 7)

A compound of claim 7, wherein m is 1 to 3 and R3 and R4 is independently selected from H, hydroxyl, optionally substituted C1-C6 alkyl.

### Claim 9 (depends on 3)

A compound of claim 3, wherein the sub-formulae is (Ib) and m′ is 0 or 1 and R3 and R4 is independently selected from H, hydroxyl, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl.

### Claim 10 (depends on 9)

A compound of claim 9, wherein m′ is 1 and R3 and R4 is independently selected from H, hydroxyl, optionally substituted C1-C6 alkyl.

### Claim 11 (depends on 9)

A compound of claim 9, wherein m′ is 0.

### Claim 12 (depends on 1)

A compound of claim 1, wherein R3 and R4 is H and H, or methyl and methyl.

### Claim 13

A compound of formula (II) or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer or tautomer thereof:
wherein R1 is selected from optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted 6-membered heteroaryl; and
R2 is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted acyl, or optionally substituted oxyacyl; and
R3 and R4 are independently selected from H and optionally substituted C1-C3 alkyl; and
m is an integer selected from 2 to 5.

### Claim 14 (depends on 13)

A compound of claim 13, wherein m is 2 or 3.

### Claim 15 (depends on 13, 14)

A compound of claim 13 or 14 which are represented by formula (IIa) and (IIb):
wherein R1, R2, R3, and R4 are as defined above for compounds of formula (II).

### Claim 16

A compound of formula (III) or pharmaceutically acceptable salts, solvates, prodrugs, stereoisomers or tautomers thereof:
wherein R1 is selected from optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted 6-memberd heteroaryl;
R2 is selected from H, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted acyl, or optionally substituted oxyacyl;
Y is selected from optionally substituted cycloalkyl, optionally substituted heterocyclyl, or optionally substituted cycloalkenyl.
L is a single bond;
R3 and R4, if present, are independently H or C1-C3 alkyl; and
m′ is 0 or 1.

### Claim 17

A compound of formula (IV) or a pharmaceutically acceptable salt, solvate, prodrug, stereoisomer or tautomer thereof:
wherein R1 is selected from optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted 6-membered heteroaryl; and
Z is optionally substituted C5-C10 N-heterocyclyl.

### Claim 18

A compound of formula (V) or pharmaceutically acceptable salts, solvates, prodrugs, stereoisomers or tautomers thereof:
wherein T is a benzofused C5-C10 N-containing heterocyclyl.

### Claim 19

A compound selected from:

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A method of medically treating a disease, disorder, or condition which would benefit from modulation of α7nAChR, said method including the step of administering an effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of a compound according to any one of claims 1 to 19 or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for treating a disease, disorder or condition which would benefit from modulation of α7 nAChR.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

Use of a compound according to any one of claims 1 to 19 or a pharmaceutical salt thereof, for treating a disease, disorder or condition which would benefit from modulation of α7 nAChR.

### Claim 23 (depends on 20, 21, 22)

A method or use according to any one of claim 20, 21 or 22, wherein the disease, disorder or condition which would benefit from modulation of α7 nAChR is a disease, disorder or condition in which the benefit comes from the negative allosteric modulation of α7 nAChR.

### Claim 24 (depends on 23)

A method or use according to claim 23 wherein the disease, disorder or condition in which the benefit comes from the negative allosteric modulation of α7 nAChR is a disease, disorder or condition selected from anxiety, depression, or a stress-related disorder.
